Distinct roles of the adaptor protein Shc and focal adhesion kinase in integrin signaling to ERK

被引:151
作者
Barberis, L
Wary, KK
Fiucci, G
Liu, F
Hirsch, E
Brancaccio, M
Altruda, F
Tarone, G
Giancotti, FG
机构
[1] Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA
[2] Univ Turin, Dipartimento Genet Biol & Chim Med, I-10100 Turin, Italy
关键词
D O I
10.1074/jbc.M002487200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
It has been proposed that integrins activate ERK through the adaptor protein She independently of focal adhesion kinase (FAK) or through FAK acting on multiple target effecters, including She. We show that disrupt ion of the actin cytoskeleton by cytochalasin D causes a complete inhibition of FAK. but does not inhibit She signaling and activation of ERK. We have then generated primary fibroblasts carrying a targeted deletion of the segment of beta (1) subunit cytoplasmic domain required for activation of FAK Analysis of these cells indicates that FAK is not necessary for efficient tyrosine phosphorylation of She, association of She with Grb2, and activation of ERK in response to matrix adhesion. In addition, integrin-mediated activation of FAK does not appear to be required for signaling to ERK following growth factor stimulation. To examine if FAK could contribute to the activation of ERK in a cell type-specific manner through the Rap1/B-Raf pathway, we have used Swiss-3T3 cells, which in contrast to primary fibroblasts express B-Raf. Dominant negative studies indicate that She mediates the early phase and peak, whereas FAK, p130(CAS), Crk, and Rap1 contribute to the late phase of integrin-dependent activation of ERK in these cells. In addition, introduction of B-Raf enhances and sustains integrin-mediated activation of ERK in wild-type primary fibroblasts but not in those carrying the targeted deletion of the beta (1) cytoplasmic domain. Thus, the She and FAK pathways are activated independently and function in a parallel fashion. Although not necessary for signaling to ERK in primary fibroblasts, FAH may enhance and prolong integrin-mediated activation of ERK through p130(CAS), Crk, and Rap1 in cells expressing B-Raf.
引用
收藏
页码:36532 / 36540
页数:9
相关论文
共 65 条
[1]   Anchorage-dependent cell cycle progression [J].
Assoian, RK .
JOURNAL OF CELL BIOLOGY, 1997, 136 (01) :1-4
[2]   THE MOUSE B-RAF GENE ENCODES MULTIPLE PROTEIN ISOFORMS WITH TISSUE-SPECIFIC EXPRESSION [J].
BARNIER, JV ;
PAPIN, C ;
EYCHENE, A ;
LECOQ, O ;
CALOTHY, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23381-23389
[3]   The association of CRKII with C3G can be regulated by integrins and defines a novel means to regulate the mitogen-activated protein kinases [J].
Buensuceso, CS ;
O'Toole, TE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (17) :13118-13125
[4]   Focal adhesions, contractility, and signaling [J].
Burridge, K ;
ChrzanowskaWodnicka, M .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 1996, 12 :463-518
[5]   The talin head domain binds to integrin β subunit cytoplasmic tails and regulates integrin activation [J].
Calderwood, DA ;
Zent, R ;
Grant, R ;
Rees, DJG ;
Hynes, RO ;
Ginsberg, MH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (40) :28071-28074
[6]   INTERACTION OF FOCAL ADHESION KINASE WITH CYTOSKELETAL PROTEIN TALIN [J].
CHEN, HC ;
APPEDDU, PA ;
PARSONS, JT ;
HILDEBRAND, JD ;
SCHALLER, MD ;
GUAN, JL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (28) :16995-16999
[7]  
CHEN QM, 1994, J BIOL CHEM, V269, P26602
[8]   1997 keystone symposium on signal transduction by cell adhesion receptors [J].
Clark, EA ;
Hynes, RO .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1997, 1333 (03) :R9-R16
[9]   ACTIVATION OF MAP KINASE KINASE IS NECESSARY AND SUFFICIENT FOR PC12 DIFFERENTIATION AND FOR TRANSFORMATION OF NIH 3T3 CELLS [J].
COWLEY, S ;
PATERSON, H ;
KEMP, P ;
MARSHALL, CJ .
CELL, 1994, 77 (06) :841-852
[10]   C3G is tyrosine-phosphorylated after integrin-mediated cell adhesion in normal but not in Bcr/Abl expressing cells [J].
de Jong, R ;
van Wijk, A ;
Heisterkamp, N ;
Groffen, J .
ONCOGENE, 1998, 17 (21) :2805-2810